Citanest
Every registration of this product has been cancelled.
N-(2-Methylphenyl)-2-(propylamino)propanamide
Drag to rotate; arrow keys step through the atoms. Structure from PubChem CID 4906.
Registration
- Applicants
- 1
- Registrations
- 1
Applicants and registrations
| Applicant | Brands | Dosages | Registrations | Schedule | Leaflets |
|---|---|---|---|---|---|
| Adcock ingram limitedCancelled | Citanest | 4 % | P0172 | Not determined | None |
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Citanest 4 % * EACH 1 ml CONTAINS PRILOCAINE HYDROCHLORIDE 40 mg | 4 % | P0172P/4/172 | Cancelled | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Prilocaine
- when intended for ophthalmic or parenteral use; (S4)
- except in topical preparations containing 10 percent or less of prilocaine. (S1)
Consolidated Schedules 06 July 2026, lines 7638 to 7642
S1: Prilocaine
- in topical preparations containing 10 percent or less of prilocaine;
- except when intended for ophthalmic or parenteral use. (S4)
Consolidated Schedules 06 July 2026, lines 1031 to 1035
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
Background
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.